Clinical Wins and Legal Headwinds Collide for Bayer Ahead of Landmark July Rulings
13.06.2026 - 21:15:01 | boerse-global.de
Bayer finds itself caught between a promising pipeline and a punishing legal calendar. The German pharmaceuticals and crop science group has scored a significant clinical victory with its kidney drug Kerendia, while simultaneously facing make-or-break courtroom deadlines in the United States. Investors are watching both fronts intently, but it is the mounting glyphosate litigation — not the encouraging trial data — that is currently dictating the stock’s direction.
A phase III study for Kerendia, known as FIND-CKD, hit its primary endpoint by demonstrating a meaningful slowdown in kidney function deterioration among non-diabetic patients. The drug also cut cardiovascular risks such as heart failure compared with placebo. Bayer presented the results at the European Renal Association congress and followed up with a publication in the New England Journal of Medicine — a double release that the pharmaceutical industry regards as a strong endorsement. Kerendia is already approved for diabetes-related kidney disease, but the new indication opens up a much larger pool: roughly 850 million people worldwide suffer from chronic kidney disease, and more than half are non-diabetic.
Alongside this clinical progress, Bayer is also reshaping its management team. The consumer health division has installed a new leadership structure aimed at accelerating the “Road to Billions” growth strategy. Samantha Avivi, previously head of North American operations, becomes global marketing chief for over-the-counter medicines. For the first time, Bayer has appointed a standalone president for the US market. On the pharma side, Dr. Jost Reinhard will assume leadership of the radiology business from August. The changes signal a push for sharper execution across the group’s commercial units.
Yet none of this operational news has been able to lift the share price. Bayer stock closed last Friday at €36.06, barely above its 200-day moving average of €35.99. The year-to-date decline stands at roughly five percent, and the shares trade far below the 52-week high of nearly €50. The reason is clear: legal uncertainty continues to suffocate investor sentiment.
Should investors sell immediately? Or is it worth buying Bayer?
The company faces two pivotal court events in the coming weeks. The US Supreme Court is expected to rule by early July on Monsanto v. Durnell, a case that will determine whether federal pesticide law preempts state-level warning claims. A favourable decision could gut approximately 80 percent of the more than 100,000 outstanding Roundup lawsuits. Separately, a hearing set for 9 July in St. Louis will consider final approval of a proposed $7.25 billion settlement intended to resolve roughly 65,000 current claims.
That settlement, however, is under fire. Critics filed an objection in May, branding the deal a “gag order” that benefits Bayer at the expense of genuine accountability. Some plaintiffs are also attempting to shift the case to federal court. The agreement remains fragile: Bayer can walk away if too few claimants opt in, and the opt-out deadline passed in early June. CEO Bill Anderson has so far declined to disclose how many claimants have chosen to leave the deal.
While the legal machinery grinds on, Bayer’s underlying business shows signs of life. The European Medicines Agency is reviewing Asundexian, a stroke-prevention drug that the company urgently needs to replace fading revenues from its blockbuster Xarelto, whose sales slumped by a third to €2.6 billion in 2025. First-quarter revenue rose 4.1 percent on a currency-adjusted basis, and operating profit came in at around €4.4 billion. But with the Roundup liability still unquantified and the Supreme Court decision hanging in the balance, the market is refusing to price in any operational improvement.
Bayer at a turning point? This analysis reveals what investors need to know now.
For now, Bayer remains a binary bet on the US judiciary. The stock is trapped in a narrow band, waiting for the gavel to fall. Only after both court dates have passed — the Supreme Court ruling expected before July’s end and the settlement hearing on 9 July — will investors finally know whether the fundamental recovery can finally translate into a share price rebound.
Ad
Bayer Stock: New Analysis - 13 June
Fresh Bayer information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
